SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo

The emergence of Plasmodium falciparum resistance to artemisinin combination therapy (ACT) is a worrying development. It calls for close surveillance to monitor the efficacy of the drugs. The objectives of this study were to determine the performance of SD Bioline malaria AgPf(HRP-2/pLDH) 3 band Rap...

Full description

Saved in:
Bibliographic Details
Main Authors: Kilauzi, Albert L., Tshikuka Mulumba, Jose G., Magafu, Mgaywa G. M. D., Matchaba-Hove, Reginald, Tapera, Roy, Magafu, Naoko S., Tamfum, Jean J. M.
Format: Article
Language:English
Published: African Field Epidemiology Network 2016
Subjects:
Online Access:http://hdl.handle.net/11408/974
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1779905259928289280
author Kilauzi, Albert L.
Tshikuka Mulumba, Jose G.
Magafu, Mgaywa G. M. D.
Matchaba-Hove, Reginald
Tapera, Roy
Magafu, Naoko S.
Tamfum, Jean J. M.
author_facet Kilauzi, Albert L.
Tshikuka Mulumba, Jose G.
Magafu, Mgaywa G. M. D.
Matchaba-Hove, Reginald
Tapera, Roy
Magafu, Naoko S.
Tamfum, Jean J. M.
author_sort Kilauzi, Albert L.
collection DSpace
description The emergence of Plasmodium falciparum resistance to artemisinin combination therapy (ACT) is a worrying development. It calls for close surveillance to monitor the efficacy of the drugs. The objectives of this study were to determine the performance of SD Bioline malaria AgPf(HRP-2/pLDH) 3 band Rapid Diagnostic Test (RDT) against Giemsa-stained blood smear and evaluate the suitability of this test in assessing the therapeutic efficacy of ACT in pediatric malaria patients in the Democratic Republic of the Congo (DRC). Methods: Five hundred and one patients with malaria symptoms were screened for P. falciparum in Kinshasa, DRC. Of the 166 patients who tested positive for P. falciparum at recruitment (day 0), 103 consented to participate in this study and were followed up and retested for P. falciparum on day 3, day 7, day 14, day 21 and day 28. Results: Sensitivity and specificity of the test were significantly high on day 0 and so were their positive and negative predictive values. Higher proportions of false positive cases were observed on the HRP-2 band irrespective of patient parasite densities during the follow up but these were barely seen on the pLDH band. Some patients turned positive during follow up but pLDH readings remained consistent with blood smear readings. Conclusion: SD Bioline malaria AgPf(HRP-2/pLDH) RDT demonstrated high performance in DRC. Thus, the test can be employed to assess the efficacy of ACT in pediatric malaria patients and prioritize areas that require the deployment of advanced testing like polymerase chain reaction (PCR).
format Article
id ir-11408-974
institution My University
language English
publishDate 2016
publisher African Field Epidemiology Network
record_format dspace
spelling ir-11408-9742022-06-27T13:49:06Z SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo Kilauzi, Albert L. Tshikuka Mulumba, Jose G. Magafu, Mgaywa G. M. D. Matchaba-Hove, Reginald Tapera, Roy Magafu, Naoko S. Tamfum, Jean J. M. Malaria, AgPf(HRP-2/pLDH) RDT, artemisinin combination therapy Democratic Republic of the Congo The emergence of Plasmodium falciparum resistance to artemisinin combination therapy (ACT) is a worrying development. It calls for close surveillance to monitor the efficacy of the drugs. The objectives of this study were to determine the performance of SD Bioline malaria AgPf(HRP-2/pLDH) 3 band Rapid Diagnostic Test (RDT) against Giemsa-stained blood smear and evaluate the suitability of this test in assessing the therapeutic efficacy of ACT in pediatric malaria patients in the Democratic Republic of the Congo (DRC). Methods: Five hundred and one patients with malaria symptoms were screened for P. falciparum in Kinshasa, DRC. Of the 166 patients who tested positive for P. falciparum at recruitment (day 0), 103 consented to participate in this study and were followed up and retested for P. falciparum on day 3, day 7, day 14, day 21 and day 28. Results: Sensitivity and specificity of the test were significantly high on day 0 and so were their positive and negative predictive values. Higher proportions of false positive cases were observed on the HRP-2 band irrespective of patient parasite densities during the follow up but these were barely seen on the pLDH band. Some patients turned positive during follow up but pLDH readings remained consistent with blood smear readings. Conclusion: SD Bioline malaria AgPf(HRP-2/pLDH) RDT demonstrated high performance in DRC. Thus, the test can be employed to assess the efficacy of ACT in pediatric malaria patients and prioritize areas that require the deployment of advanced testing like polymerase chain reaction (PCR). 2016-04-24T08:56:28Z 2016-04-24T08:56:28Z 2015 Article 1937- 8688 http://hdl.handle.net/11408/974 en Pan African Medical Journal;Vol. 22, No. 304 open African Field Epidemiology Network
spellingShingle Malaria, AgPf(HRP-2/pLDH) RDT, artemisinin combination therapy
Democratic Republic of the Congo
Kilauzi, Albert L.
Tshikuka Mulumba, Jose G.
Magafu, Mgaywa G. M. D.
Matchaba-Hove, Reginald
Tapera, Roy
Magafu, Naoko S.
Tamfum, Jean J. M.
SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title_full SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title_fullStr SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title_full_unstemmed SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title_short SD Bioline malaria antigen Pf (HRP-2/pLHD) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the Democratic Republic of the Congo
title_sort sd bioline malaria antigen pf (hrp-2/plhd) for assessing efficacy of artemisinin combination therapy against plasmodium falciparum in pediatric patients in the democratic republic of the congo
topic Malaria, AgPf(HRP-2/pLDH) RDT, artemisinin combination therapy
Democratic Republic of the Congo
url http://hdl.handle.net/11408/974
work_keys_str_mv AT kilauzialbertl sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT tshikukamulumbajoseg sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT magafumgaywagmd sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT matchabahovereginald sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT taperaroy sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT magafunaokos sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo
AT tamfumjeanjm sdbiolinemalariaantigenpfhrp2plhdforassessingefficacyofartemisinincombinationtherapyagainstplasmodiumfalciparuminpediatricpatientsinthedemocraticrepublicofthecongo